Page 20 - Genentech News Today

Cell-free DNA testing company Natera, Inc. (NTRA) announced Friday an analysis from the IMvigor011 study that was presented at the European Association of Urology (EAU) Congress 2024 in Paris, France.

These FDA-approved therapies are used to treat lymphoma after 2 or more lines of therapy and represent significant advancements in the treatment of lymphoma.

The City of Pleasanton will face some economic challenges and difficult financial decisions in the coming years, but it will emerge as “One Pleasanton” — a city committed to its

LEXINGTON, Mass., April 4, 2024 /PRNewswire/ -- Curis, Inc. , a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James...

Some of South City’s largest biotech firms may soon vote to impose additional taxes on their own properties as a way to boost transportation infrastructure on the east side of

The Mark Foundation for Cancer Research, a leading nonprofit dedicated to advancing research that transforms the prevention, diagnosis, and treatment of cancer, proudly announces the appointment of new members to its Scientific Advisory and Industry Advisory Committees.

CARLSBAD, Calif., April 01, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a

Operator: Good day, everyone, and welcome to Affimeds Fourth Quarter and Full Year 2023 Earnings and Corporate Update Call. At this time all participants are in a listen-only mode.

Operator: Welcome, everyone, to the Matinas BioPharma 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

Dr Schmid discusses considerations for applying recent data updates in HER2-positive breast cancer management to clinical practice.